TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Scandinavian Bell's Palsy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Be in good general health and between 18 and 75 years of age.~2. Have an acute peripheral unilateral idiopathic facial palsy.~3. Not more than 72 hours must have passed after onset of palsy before initiating study medication.~4. The subjects must provide their freely given written informed consent.~Exclusion Criteria:~1. Subjects who have used any antiherpetic medication, except locally applied formulations, within the last 2 weeks.~2. Subjects with ongoing systemic steroid medication for another disease.~3. Pregnant women or nursing mothers.~4. Subjects with diabetes.~5. Subjects presently suffering from gastric or duodenal ulcers. If there is a history of previous peptic ulcers or dyspepsia prophylactic medication must be prescribed and taken during study.~6. Subjects with a history of tuberculosis.~7. Subjects with psychiatric diagnosis that are at risk to be influenced by the study drugs or that might affect the patient´s ability to complete this study.~8. Subjects with a hypertension not well controlled.~9. Subjects with a present, or a history of, serious heart disease.~10. Subjects with a history of glaucoma.~11. Subjects with a history of hepatic disease.~12. Subjects with other neurological diseases.~13. Subjects with a history of renal diseases or a known creatinine clearance of \< 30mL/min.~14. Subjects with acute otitis or a history of ipsilateral chronic otitis.~15. Subjects with a history of recent head injury.~16. Fertile, sexually active women not employing acceptable methods of contraception and/or women planning to become pregnant during the period with intake of study medication.~17. Subjects with a history of immunodeficiency syndromes.~18. Subjects with an allergy or sensitivity to aciclovir or valaciclovir, famciclovir or ganciclovir.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed the qualifying OB-202 trial~* If females of child-bearing potential, subjects must be using adequate contraception~* Provide written informed consent~* Be willing and able to comply with scheduled study visits, treatment plan, lab tests and other study procedures~Exclusion Criteria:~* Subjects who have developed one or more morbidities during the OB-202 trial that would pose a safety concern

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Naive or experienced patients with genotype 1 compensated cirrhosis~Exclusion Criteria:~* HIV and hepatitis B infection, active hepatocellular carcinoma (HCC), decompensated cirrhosis, history of organ transplant, severe psychiatric disorders or treatment with drugs that showed an interaction with antiviral treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 82 Years
- Healthy Volunteers: f

Study Arms:
- Group I (<65 years) (Type: ACTIVE_COMPARATOR): Group I treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
- Group II (>65 years) (Type: ACTIVE_COMPARATOR): Group II treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have endoscopically confirmed erosive esophagitis as defined by the Los Angeles (LA) Classification Grading System (A-D)~Exclusion Criteria:~* Subject has a positive Campylobacter-like organisms (CLO) test for Helicobacter (H.) pylori.~* Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists or sucralfate, drugs with significant anticholinergic effects, misoprostol or prokinetics~* Use of antacids \[except for study supplied Gelusil®\]~* Need for continuous anticoagulant therapy (blood thinners)~* Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus~* History of dilatation of esophageal strictures, other than Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter)~* Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition.~* History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer.~* Acute upper gastrointestinal hemorrhage within 4 weeks of the screening endoscopy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexlansoprazole MR 60 mg QD (Type: EXPERIMENTAL): None
- Dexlansoprazole MR 90 mg QD (Type: EXPERIMENTAL): None
- Lansoprazole 30 mg QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults, 18-60 years with sputum smear positive pulmonary TB~* New cases only~* Gender, both~* Consent to enroll in the study~Exclusion Criteria:~* Hypercalcaemia (serum calcium \> 2.6 mmol/L) identified at baseline~* Taking vitamin D~* Pregnant and lactating~* Any known liver or kidney function abnormality, malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Active Sodium Phenylbutyrate and active cholecalciferol (Type: ACTIVE_COMPARATOR): 500 mg sodium phenylbutyrate (4-phenylbutyric acid, sodium salt) in tablet form twice daily and 5000 IU of cholecalciferol once daily will be given orally for 2 months
- Placebo Sodium Phenylbutyrate plus active cholecalciferol (Type: ACTIVE_COMPARATOR): Drug: Cholecalciferol Placebo: Sodium Phenylbutyrate
- Active Sodium Phenylbutyrate and placebo cholecalciferol (Type: ACTIVE_COMPARATOR): Drug: Sodium Phenylbutyrate Placebo: cholecalciferol
- Placebo Sodium Phenylbutyrate plus placebo cholecalciferol (Type: PLACEBO_COMPARATOR): Placebo Sodium Phenylbutyrate Placebo cholecalciferol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Young patients aged 18-50 years inclusive or Elderly patients aged 65 years and over~* Patients must have a confirmed diagnosis of ET.~* Currently receiving anagrelide hydrochloride at a stable maintenance dose \< 5 mg/day for at least 4 weeks.~Exclusion Criteria:~* Diagnosis of any other myeloproliferative disorder.~* Current use of tobacco in any form (e.g. smoking or chewing)~* Treatment with any known enzyme altering agents (barbiturates, phenothiazines, cimetidine etc.) within 30 days prior to or during the study.~* Patients for whom use of another cytoreductive agent in addition to anagrelide is considered necessary for control of platelet count.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Younger Participants (18-50 years) (Type: EXPERIMENTAL): None
- Elderly Participants (≥65 years) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Secretion in Diabetes Before and After Glycemic Control

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aim 1:~  * (non-diabetics)~    * male/female 30-65 yrs old,~   * free of active medical disease,~   * no history of diabetes.~ * (diabetics)~    * HbA1c=6.5-8.5,~   * treated with metformin, a sulfonylurea, or combination,~   * Stable body wt with BMI 28-40.~* Aim 2: Same as above~* Aim 3: Diabetic with HgA1c 8.0-9.5~Exclusion Criteria:~* Aim 1: For both groups: no history of: pancreatitis, cardiac, gastrointestinal, renal or liver disease.~* Aim 2: Same as above~* Aim 3: Same as above, plus a diagnosis of incipient diabetic nephropathy severe nonproliferative, or proliferative retinopathy.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Intervention: Insulin glargine treatment. The study is designed as a within subjects comparison of insulin secretion in type 2 diabetic patients before and after 2 months of insulin treatment to reduce blood glucose. Insulin secretion will be determined with a hyperglycemic clamp using 20% dextrose, and ingestion of an oral glucose solution (75 g).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent/assent~* At least 12 years of age at screening~* General good health~* Persistent asthma for ≥3 months, with an FEV1 50-80% predicted and ≥15% reversibility~* Taking inhaled corticosteroids at a stable dose (≤ equivalent of 500mcg of fluticasone propionate/day) for at least 4 weeks prior to the Screening Visit.~* Ability to perform spirometry in an acceptable manner as per protocol guidelines~* Other inclusion criteria apply~Exclusion Criteria:~* A known hypersensitivity to albuterol or any of the excipients in the formulations.~* History of a respiratory infection or disorder that has not resolved within 1 week preceding the Screening Visit (SV).~* History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation.~* Any asthma exacerbation requiring oral corticosteroids within 3 months of the SV. A subject must not have had any hospitalization for asthma within 6 months prior to the SV.~* Hospitalization due to asthma exacerbation 2 or more times in the past year~* Initiation of immunotherapy or dose escalation during the study period~* Other exclusion criteria apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo MDPI (Type: PLACEBO_COMPARATOR): Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
- Albuterol MDPI (Type: EXPERIMENTAL): Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Intravenous Thrombolytics in Stroke on Awakening

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater or equal to 18 years, and lower or equal to 80 years.~* Signs and symptoms of acute ischemic stroke.~* Symptoms present upon awakening.~* Arriving to the Emergency Department within 4.5 hours of awakening. Treatment with IV tPA must be initiated prior to 4.5hours from waking up.~* NIHSS \>3~* A non-contrast head CT without hemorrhage and without hypodensity more than 1/3 of the middle cerebral artery (MCA) territory; or MRI demonstrating no hemorrhage, and with a diffusion-weighted imaging (DWI) lesion no greater than 70 mL and FLAIR without a well defined hyperintense lesion that is more than 1/3 of the MCA territory.~* Pre-morbid modified Rankin score of 0 or 1.~Exclusion Criteria:~* Rapidly improving deficit to an NIHSS less than 3.~* Sustained systolic blood pressure greater than 185 mmHg or diastolic blood pressure greater than 110 mmHg despite treatment.~* Glucose less than 50 mg/dL.~* Stroke or head trauma within last 3 months.~* History of intracranial hemorrhage. Symptoms of subarachnoid hemorrhage.~* Major surgery within 14 days.~* Gastrointestinal (GI)/Genito-urinary (GU) hemorrhage within 21 days.~* International normalized ratio (INR) \> 1.7.~* Heparin within 48 hours with an elevated activated partial thromboplastin time (aPTT).~* Platelet count less than 100,000.~* Presumed septic embolus or suspicion of bacterial endocarditis.~* Suspicion of aortic dissection.~* Use of anticoagulants such as dabigatran, rivaroxaban, apixaban, enoxaparin.~* Pregnant or lactating women.~* Known allergy or sensitivity to tPA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IV tPA (Type: EXPERIMENTAL): Treatment will be initiated within 4.5 hours of awakening, for patients who meet inclusion criteria

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female patients aged ≥40 with stable moderate to severe COPD (GOLD guidelines).~* Post-salbutamol (FEV1) \< 80% and ≥ 30% of predicted normal value and Post-salbutamol FEV1/FVC \< 70%.~* Current or ex-smokers of 10 ≥pack-years.~Exclusion Criteria:~* Patients with no history or current diagnosis of asthma.~* No evidence of an exacerbation within 6 weeks prior to the screening visit.~* No evidence of clinically significant respiratory and/or cardiovascular conditions or laboratory abnormalities.~* No contraindication to use of anticholinergic drugs such as known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aclidinium bromide (Type: EXPERIMENTAL): Aclidinium bromide 400 µg administered twice per day during 6 weeks of treatment
- Tiotropium (Type: ACTIVE_COMPARATOR): Tiotropium bromide 18 µg administered once per day during 6 weeks of treatment
- Placebo (Type: PLACEBO_COMPARATOR): Placebo comparator administered during 6 weeks of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female infant born at \>36 weeks of gestation and aged 2 months (42 to 98 days) at the time of consent (the day of birth is considered day of life 1).~* Healthy infant determined by medical history, physical examination, and clinical judgment to be eligible for the study.~Exclusion Criteria:~* Previous vaccination with licensed or investigational pneumococcal vaccine.~* Prior receipt of diphtheria, tetanus, pertussis, or polio vaccines.~* Previous receipt of \>1 dose of hepatitis B vaccine.~* Prior hepatitis B vaccine must have been administered at age \<30 days.~* Major known congenital malformation or serious chronic disorder. Receipt of blood/plasma products or immunoglobulins

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- Multivalent (Type: EXPERIMENTAL): Pneumococcal conjugate vaccines
- Control (Type: ACTIVE_COMPARATOR): 13vPnC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving ADHD Teen Driving

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 16-19.~2. Must meet DSM-5 ADHD criteria for ADHD-Predominantly Inattentive Presentation or ADHD-Combined Presentation based on the K-SADS interview.~3. Possess a valid driver's license and regularly spend at least 3 hours per week engaged in unsupervised driving.~4. IQ ≥80 as measured by the Wechsler Abbreviated Intelligence Scale-II (WASI-II)~5. Parent willing to participate..~Exclusion Criteria:~1. On ADHD medication that cannot be washed out on assessment days.~2. Drug or alcohol dependence according to K-SADS interview.~3. On psychotropic or neuroleptic medications.~4. Require eye glasses (contacts acceptable) for driving (corrective vision restriction on driver's license).

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- FOCAL+Training (Type: EXPERIMENTAL): None
- Rules of the Road Training (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combined Bio- and Neuro- Feedback vs. Varenicline Use for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Being continuous tobacco smokers (\>10 cigarettes per day) for at least 6 months~* Being unemployed for at least 3 months~* Being diagnosed with Asthma~* Being diagnosed with C.O.P.D.~* Age \< 35, for the group of Young Unemployed~* Age \>35 years, for the groups of Asthma and C.O.P.D. patients~Exclusion Criteria:~* Diagnosed neurological, mental or psychiatric illness~* Drug-resistance epilepsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- COPD Patients (Type: EXPERIMENTAL): C.O.P.D. patients: Presence of a post-bronchodilator forced expiratory volume at one second (FEV1) / forced vital capacity (FVC) \< 0.70 with symptoms as dyspnea, chronic cough, chronic sputum production~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Passive Control
- Asthma Patients (Type: EXPERIMENTAL): Asthma patients: Presence of 2 or more of symptoms of airflow obstruction (cough, wheezing, dyspnea). Airflow obstruction at least partially reversible demonstrated by spirometry with FEV1 increased by \>12% following b2 agonist inhalation) or evidence of bronchial hyperresponsiveness by metacholine provocation test (demonstrated by provocative concentration causing a 20% fall (PC20) \<8 mg or mannitol provocation test (with FEV1 decrease of 15%)~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Passive Control
- Smokers (Type: EXPERIMENTAL): Smokers will consist of a group of patients that are under the age of 35, unemployed and healthy according to a standard clinical evaluation.~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Sham Neurofeedback~Passive Control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete